RxDoctor Payments DataLook up a doctor →

Joanna Lopez, MD

Gastroenterology · Miami, FLNPI 1871889345

Payments from drug & device makers

$669,664in general payments, 2019–2025

Across 776 payments — averaging $862.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$225K
  • Johnson & Johnson$202K
  • AbbVie$136K
  • Janssen Scientific Affairs, LLC$55K
  • E.r. Squibb & Sons, L.L.C.$36K
  • Ferring Pharmaceuticals Inc.$5K
  • plus $11K from 26 others

What the payments were for

  • Consulting fees$28,2534%
  • Speaking & faculty fees$556,87583%
  • Travel & lodging$66,99710%
  • Food & beverage$17,4313%
  • Education$1080%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$669,664 in reported general payments places this provider in the 95th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$215,237
Medicare patients
206
Services billed
7,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab15$429,798
RinvoqUpadacitinib36$268,735
CreonLipase/Protease/Amylase25$62,901
Mesalamine69$30,641
LinzessLinaclotide13$10,266
SutabSod Sulf/Pot Chloride/Mag Sulf54$8,914
ClenpiqSod Picosulf/Mag Ox/Citric Ac33$5,640
Mesalamine ErMesalamine11$3,320
Cholestyramine LightCholestyramine19$1,122
Pantoprazole Sodium94$1,108
Famotidine78$1,075
CholestyramineCholestyramine (With Sugar)18$731
Omeprazole60$730
Dicyclomine Hcl30$710
Esomeprazole Magnesium39$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$202,054$429,79815 claims
AbbVieRinvoq, Creon, Linzess$135,952$341,90174 claims
Braintree Laboratories, Inc.Sutab$17$8,91454 claims
Ferring Pharmaceuticals Inc.Clenpiq$4,650$5,64033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →